Arcellx, Inc.
ACLX
Peringkat dalam Saham
#2787
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Harga Saham
$115.07
Terakhir disinkronkan: 2026-05-15
Kapitalisasi Pasar
$6.73B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
34.40%
Negara
US
Perdagangan Arcellx, Inc. (ACLX)
Kategori
Healthcare
Pendapatan untuk Arcellx, Inc. (ACLX)
Pendapatan pada Dec 2025 TTM: $22.29M
Menurut laporan keuangan terbaru dari Arcellx, Inc., pendapatan saat ini (TTM) adalah $22.29M. Pada tahun 2023, perusahaan menghasilkan pendapatan sebesar $110.32M peningkatan dibandingkan pendapatan pada tahun 2022 yang sebesar 0.00. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Arcellx, Inc. dari 2018 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2026 (TTM) | $22.29M | -79.35% |
| 2024 | $107.94M | -2.16% |
| 2023 | $110.32M | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| $12.62B | 56,546.77% |
US
|
|
| $2.23B | 9,897.31% |
US
|
|
| $15.74B | 70,546.72% |
AU
|
|
| $6.02B | 26,918.25% |
NL
|
|
| - | - |
CH
|
